Trial Profile
Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs GPA-TriMAR-T-cell-therapy (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Timmune Biotech
- 04 Sep 2018 New trial record